I'm dying of a fatal disease. Bureaucrats shouldn't decide how doctors can try to save me
Tragically, the federal government is standing in the way.
I'm not alone; tens of millions of Americans suffer from rare diseases. And while I believe we have entered a "Golden Age" of personalized medicine tailored around a patient's DNA, regulatory roadblocks often force us to wait years to access treatments that could help. We need to break through this logjam so patients can access cutting-edge treatments today.
My disease is Duchenne muscular dystrophy (DMD) — a rare, genetic disorder that causes my muscles to waste away. Patients lose their ability to walk around the ages 9 to 12 and become completely dependent on a power-wheelchair. Then they noticeably lose function of their arms in their teens, and eventually lose their life in their mid-20s as the muscles responsible for breathing are affected, as well as the heart muscle.
I decided early on not to let this disease define me — or stop me. At 15, I founded a nonprofit organization called Destroy Duchenne. I went on to become a bestselling author, public speaker, Hollywood writer and producer, biotech consultant to five companies, investor, and recognized Key Opinion Leader (KOL) in DMD.
Yet I still know the brutality and pain this disease causes. My younger brother, who is 17, also has DMD. So did my other younger brother, who passed away from the disease at age 14. Duchenne affects not just the person with the disease, but everyone around them, as it steals the person away from those who love them.
Fortunately, I'm optimistic about innovation in the medical field. As someone who works in the biotech industry, I know of countless advances currently in the works that are going to change the way we deal with diseases. With the rise of AI, even more progress can be made faster and cheaper, and drugs can be even safer from their inception.
What is critical with rare genetic diseases is time. It's nearly always better to intervene earlier, as it is easier to preserve existing function and overcome some of the effects of the disease. For example, younger patients with Duchenne tend to have more muscle.
They also tend to have less fibrosis (scar tissue) and fat infiltration — two biological effects of the disease as time progresses, which further reduce mobility. Tragically, some patients are at the end of their life, where days can make the difference between living or dying.
On average, clinical trials for new treatments take around 10 years to complete. By then, a patient's disease may have progressed beyond the point where they can be meaningfully treated — or they may have even passed away. We need legislation like the "Right to Try for Individualized Treatments." It's an innovative reform that's now law in six states that puts the power into the hands of the doctor and patient to make these critical decisions about when to try investigational new drugs that are customized based on genetics.
Right now, I can be willing to try a new treatment, the manufacturer of the treatment can be willing to allow me to try it, and a doctor can be willing to administer it — yet Uncle Sam is not willing and stops me from receiving a lifesaving treatment.
This is completely backwards. After all, doctors know their patients better than a far-off bureaucrat who doesn't even know the patient exists. Why should I have to beg the federal government for permission to try to save my own life?
The reality for me is that I'm going to die, likely before I reach middle-age. The average lifespan for people with Duchenne is 25. But it doesn't have to be that way.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
12 minutes ago
- Bloomberg
Sarepta Needs to Show FDA Elevidys Won't Cause More Deaths
The Food and Drug Administration won't sign off on Sarepta Therapeutics Inc. bringing its controversial gene therapy back to the market until the company can persuade US regulators that it won't cause more deaths, according to an official familiar with the situation. The FDA has not seen a convincing explanation as to why Sarepta's gene therapy for Duchenne muscular dystrophy, Elevidys, was tied to two fatal cases of liver failure, the official said, and there may be no single, easily addressable problem the company can quickly fix. A third fatal case of liver failure that occurred during a trial of a separate but similar Sarepta gene therapy is unquestionably relevant information to the safety of Elevidys, said the official, who declined to be identified because the agency's deliberations are private.
Axios
2 hours ago
- Axios
RFK Jr. greenlights removing preservative from flu shots
The Health and Human Services Department on Wednesday said it adopted a recommendation from Secretary Robert F. Kennedy Jr.'s vaccine advisers to remove from all influenza shots a preservative that anti-vaccine activists have suggested is linked to autism. Why it matters: The move hinged on the widely discredited belief that the mercury-containing compound, thimerosal, is harmful at the level at which it's included in vaccines. Despite the lack of evidence of harm, most Americans who get flu vaccines already receive products without thimerosal. The latest: Kennedy, in a statement, said the action fulfilled a promise to protect vulnerable populations from unnecessary mercury exposure. "Injecting any amount of mercury into children when safe, mercury-free alternatives exist defies common sense and public health responsibility," Kennedy said. "Today, we put safety first." The Centers for Disease Control customarily acts on such recommendations. But because the CDC lacks a full-time political leader, Kennedy signed the recommendation. HHS said that vaccine manufacturers confirmed that they have the capacity to replace multi-dose vials containing the preservative so that the federal Vaccines for Children program and adult vaccine supplies won't be interrupted. Kennedy's handpicked vaccine advisors voted 5-1 last month to no longer recommend that that Americans get flu shots containing thimerosal, following a presentation from a retired nurse and former president of Children's Health Defense, the anti-vaccine group with close ties to Kennedy.
Yahoo
2 hours ago
- Yahoo
Summer Covid cases are rising across the U.S. — Is it time for a vaccine?
As Covid cases begin to rise this summer, many may be wondering: What are my risks, and is it time to get another vaccine? As of July 15, Covid cases were growing or likely growing in 27 states including Texas, Illinois, Kentucky, Virginia and Ohio, according to the Centers for Disease Control and Prevention. Rates of positive Covid tests have also been increasing in recent weeks, the CDC says, specifically in the southern region of the country. N.B.1.8.1 is the current dominant variant in the United States, accounting for 43% of all new Covid cases, according to the CDC. It's an offshoot of the XVD.1.5.1 strain, a descendant of the omicron variant. N.B.1.8.1 was responsible for a surge in hospitalizations in China earlier this year. It's been nicknamed 'razor blade throat,' as there have been anecdotal reports of some people getting painful sore throats, said Dr. William Schaffner, an infectious disease expert at Vanderbilt University Medical Center in Nashville, Tennessee. Schaffner noted, however, that sore throats have been a common symptom of Covid since it first began spreading. 'I doubt the clinical spectrum of Covid has changed substantially,' Schaffner said. Do I need a Covid booster? When will the new vaccines be available? The uptick in cases comes as many Americans have likely gone a year or longer without a Covid shot. In May, the Food and Drug Administration asked drugmakers to update their Covid vaccines to target the LP.8.1 strain, a descendent of JN.1, which began spreading widely in 2023 and is another offshoot of omicron. LP.8.1 currently accounts for 31% of all new cases, per the CDC. The new shots won't be available until the fall, and are expected to be approved only for adults 65 and up and kids and adults with at least one medical condition that puts them at risk of severe illness. Healthy kids and adults who want a shot may have to find an older version or pay out of pocket. A single dose can cost as much as $140. Experts say, however, that population immunity — whether from vaccination, prior infection or both — may shield much of the public for now. 'While we don't have a lot of high level of immunity in the population right now, because it's been so long, we may have enough low level immunity to just make it a little bit harder for that virus to transmit easily from person to person,' said Andy Pekosz, an infectious disease researcher at Johns Hopkins University. Indeed, weekly hospitalization rates have remained low, suggesting that the new variant may not be leading to severe illness. The number of cases are still drastically lower than those this time last year, when the test positivity rate peaked in August at 17.9%. The 2025 season has yet to scrape 5%. Pekosz said it isn't unusual for cases to rise during the summer time, when people are likely to crowd indoors to escape the heat. However, he believes that if there is a summer surge of cases, it will be a small one. 'The variants have been around for a while and haven't caused any major surges up until date,' Pekosz said. 'So again, I'm hopeful that if we see a surge, it'll be a low level surge compared to previous years.' Dr. Ofer Levy, director of the precision vaccines program at Boston Children's Hospital, who has advised the FDA, said people who are at high risk of severe illness still may want to consider getting a Covid shot, if they can find one. High risk groups include: Older adults People with weakened immune systems Pregnant women Those with underlying health conditions, such as asthma and heart disease Getting a shot is especially important, Levy said, for those who haven't had one in over a year and whose immunity has likely waned. 'If you're in a high risk group and you're in a state where cases are rising, you may want to just get the first available appointment and get a shot to protect yourself,' he said. People at high risk can then consider getting an additional Covid shot when the updated vaccines are distributed in the fall, he said. Covid has two waves a year Schaffner, of Vanderbilt, said people in the high risk groups may also want to consider wearing a mask during indoor activities, such as the movies. Healthy adults and children may be able to wait longer before getting another shot, Levy added. 'If you're in a lower risk group, that's where things get fuzzy,' he said. 'I mean if you want a vaccine and your health care provider concurs and you can get it.' Dr. Michael Phillips, an infectious disease doctor at NYU Langone, said that he sees mostly immunocompromised and older adults test positive for the virus. For those who haven't gotten a Covid shot in years, Phillips said he doesn't think they should worry just yet. 'If you're younger, otherwise healthy, I think you're OK,' Phillips said. 'If you have underlying pulmonary disease, you know, if you're an older age group, now that's a time when you should be really talking to a doctor and saying, 'Gosh, should I be getting a booster for Covid?'' He said that the amount of positive Covid tests NYU Langone has seen has decreased 40% since February. Fatima Amaeka, a senior analyst at the Center for Outbreak Response Innovation at Johns Hopkins, said she expects the current wave to peak around September. Schaffner said to expect another wave in the late fall and winter. '[Covid] has two increases each year,' he said. 'Everyone is familiar with the winter increase that goes along with flu and RSV.' This article was originally published on Solve the daily Crossword
